These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 15309199)

  • 1. The pivotal role of nitric oxide for vascular health.
    Cooke JP
    Can J Cardiol; 2004 Aug; 20 Suppl B():7B-15B. PubMed ID: 15309199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADMA: its role in vascular disease.
    Cooke JP
    Vasc Med; 2005 Jul; 10 Suppl 1():S11-7. PubMed ID: 16444864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of asymmetric dimethylarginine and endothelial dysfunction.
    Böger RH
    Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor.
    Böger RH; Ron ES
    Altern Med Rev; 2005 Mar; 10(1):14-23. PubMed ID: 15771559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does ADMA cause endothelial dysfunction?
    Cooke JP
    Arterioscler Thromb Vasc Biol; 2000 Sep; 20(9):2032-7. PubMed ID: 10978245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials.
    Böger RH
    Vasc Med; 2005 Jul; 10 Suppl 1():S19-25. PubMed ID: 16444865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
    Siroká R; Cibulka R; Rajdl D; Racek J
    Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis.
    Weis M; Kledal TN; Lin KY; Panchal SN; Gao SZ; Valantine HA; Mocarski ES; Cooke JP
    Circulation; 2004 Feb; 109(4):500-5. PubMed ID: 14732750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA.
    Sydow K; Mondon CE; Cooke JP
    Vasc Med; 2005 Jul; 10 Suppl 1():S35-43. PubMed ID: 16444867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The biology and therapeutic potential of the DDAH/ADMA pathway.
    Arrigoni F; Ahmetaj B; Leiper J
    Curr Pharm Des; 2010; 16(37):4089-102. PubMed ID: 21247398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.
    Böger RH
    Cardiovasc Res; 2003 Oct; 59(4):824-33. PubMed ID: 14553822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond.
    Böger RH
    Ann Med; 2006; 38(2):126-36. PubMed ID: 16581698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical significance of asymmetric dimethylarginine.
    Siroen MP; Teerlink T; Nijveldt RJ; Prins HA; Richir MC; van Leeuwen PA
    Annu Rev Nutr; 2006; 26():203-28. PubMed ID: 16848705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADMA and oxidative stress.
    Sydow K; Münzel T
    Atheroscler Suppl; 2003 Dec; 4(4):41-51. PubMed ID: 14664902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired flow-mediated dilation with age is not explained by L-arginine bioavailability or endothelial asymmetric dimethylarginine protein expression.
    Gates PE; Boucher ML; Silver AE; Monahan KD; Seals DR
    J Appl Physiol (1985); 2007 Jan; 102(1):63-71. PubMed ID: 16946027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asymmetric dimethylarginine: clinical applications in pediatric medicine.
    Tain YL; Huang LT
    J Formos Med Assoc; 2011 Feb; 110(2):70-7. PubMed ID: 21377060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway.
    Vallance P; Leiper J
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1023-30. PubMed ID: 15105281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?
    Rochette L; Lorin J; Zeller M; Guilland JC; Lorgis L; Cottin Y; Vergely C
    Pharmacol Ther; 2013 Dec; 140(3):239-57. PubMed ID: 23859953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine--an explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction.
    McCarty MF
    Med Hypotheses; 2004; 63(4):699-708. PubMed ID: 15325021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymmetrical dimethylarginine plasma concentrations are related to basal nitric oxide release but not endothelium-dependent vasodilation of resistance arteries in peritoneal dialysis patients.
    Mittermayer F; Schaller G; Pleiner J; Vychytil A; Sunder-Plassmann G; Hörl WH; Wolzt M
    J Am Soc Nephrol; 2005 Jun; 16(6):1832-8. PubMed ID: 15857920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.